Butterfly Network, Inc. develops semiconductor-based ultrasound devices, programmable cloud software and AI for medical imaging and sensing. Its Ultrasound-on-Chip technology underpins handheld whole-body ultrasound systems such as Butterfly iQ, iQ+ and iQ3, along with enterprise workflow software including Compass AI and developer tools such as Butterfly Garden.
Company news commonly covers financial results, point-of-care ultrasound adoption, FDA-cleared AI tools such as its Gestational Age Tool, U.S. and international sales channels, and platform initiatives. Updates also address Butterfly Embedded, the company’s licensing and co-development effort for applying its ultrasound chip and software platform in partner-built products, as well as board and leadership changes tied to medtech, clinical strategy and commercialization.
Butterfly Network (NYSE: BFLY) will attend the 9th Annual Evercore Healthcare Conference in Miami on December 1, 2026. Joseph DeVivo, John Doherty and Megan Carlson will host one-on-one investor meetings. The company’s fireside chat is scheduled for 3:50 pm ET that day, with a webcast available through the Events & Presentations section of its investor website.
Butterfly Network (BFLY) reported third-quarter 2026 revenue of $32.6 million, exceeding the high end of its quarterly guidance. Revenue rose 52% year over year, supported partly by Embedded partnerships. U.S. revenue increased 71% to $27.5 million, while international revenue fell 5% to $5.1 million. GAAP gross margin reached 73.0%, versus negative 17.5% a year earlier, when an inventory write-down affected results.
Net loss narrowed to $12.8 million from $34.0 million; loss per share improved to $0.05 from $0.13. Adjusted EBITDA loss, a non-GAAP earnings measure, improved 85% to $1.2 million. Butterfly raised its 2026 outlook to $123 million–$126 million revenue and a $12 million–$15 million adjusted EBITDA loss. Fourth-quarter guidance calls for $31 million–$34 million revenue and a $3 million–$6 million adjusted EBITDA loss. Cash totaled $122.3 million at September 30, 2026.
Butterfly Network (NYSE: BFLY) will present at the UBS Global Healthcare Conference in Palm Beach Garden, Florida, on November 10, 2026.
CEO and Chairman Joseph DeVivo and CFO John Doherty will present and host one-on-one investor meetings. The presentation runs from 8:45 AM to 9:20 AM ET, with a webcast available through the company's investor website. Investors can contact their UBS representative to schedule a meeting.
Butterfly Network (BFLY) and the Edward Via College of Osteopathic Medicine announced a long-term alliance and joint investment in ultrasound education.
Beginning with the 2026 incoming class, VCOM intends to give every first-year student a Butterfly iQ3 device for training and subsequent practice. iQ3 devices were distributed at recent White Coat ceremonies. Butterfly is offering discounted iQ+ devices for all remaining students, including graduating fourth-year students to carry into residency and practice.
The Lighthouse Program extends the alliance beyond graduation through continued learning and remote peer collaboration. Participating physicians will contribute data through Butterfly’s cloud platform to track ultrasound use, with a focus on rural care.
Butterfly Network (NYSE: BFLY) will report its third-quarter 2026 financial results on October 29, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens to discuss financial performance and operational progress.
The live, listen-only webcast will be available on Butterfly’s Investor Relations website, with an archive posted on its events page after the call.
Butterfly Network (NYSE: BFLY) signed a multi-year research and development agreement with Bridge Neurotech to pursue non-invasive brain-computer interfaces.
Through Butterfly Embedded, Bridge will license Butterfly’s Ultrasound-on-Chip technology to explore imaging and decoding brain activity through the skull without surgery or implants. A brain-computer interface connects brain activity with a computer. The agreement includes payments to Butterfly for technology access and development milestones, plus commitments to purchase Butterfly hardware. The work aims to enable real-time brain imaging and interaction using sound; these capabilities remain development goals.
Butterfly Network (NYSE: BFLY) appointed Mike Noonen to its Board of Directors, effective October 9, 2026, expanding the board to seven directors.
Noonen will serve on the Compensation Committee and Technology Committee. He brings 30 years of semiconductor leadership experience, including roles associated with two IPOs and multiple acquisitions. He most recently served as CEO of Swave Photonics and previously led MixComm, which Sivers Semiconductors acquired in 2022. His earlier roles included executive vice president positions at GlobalFoundries and NXP Semiconductors.
Butterfly Network (NYSE: BFLY) announced that Mendaera’s Focalist system is now commercially available with its Ultrasound-on-Chip imaging technology. The offering uses a customized Butterfly iQ3 probe and marks the first Butterfly Embedded partner technology to reach the market. The companies previously announced their collaboration through the Embedded program.
Mendaera’s FDA-cleared Focalist combines handheld robotics, real-time imaging and guidance software for image-guided needle procedures, including vascular access, regional nerve blocks and organ access. Its U.S. clearance covers guidance for instrument placement during diagnostic or therapeutic procedures in pediatric and adult patients. Mendaera said Butterfly’s programmable imaging platform opens a path toward AI-enabled image interpretation and robotic action.
Butterfly Network (BFLY)/b) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 15, 2026.President and CEO Joseph DeVivo, CFO John Doherty, and Chief Accounting Officer Megan Carlson will attend, host one-on-one investor meetings, and join a fireside chat at 10:00 AM ET. A live webcast of the fireside chat will be accessible via the Events & Presentations section of Butterfly's investor website.
Butterfly Network (NYSE: BFLY) announced a multi-year licensing agreement with Merge Labs through Butterfly Embedded™, granting Merge access to Butterfly’s Poseidon Family Ultrasound-on-Chip™ technology to develop ultrasound-based brain-computer interfaces (BCI). The agreement includes upfront and milestone-based license payments, hardware purchase commitments, technology access fees, and expected ongoing royalties to Butterfly on future commercial sales. Butterfly will act as Merge’s exclusive CMOS-MEMS chip-based ultrasound partner while retaining the right to license its platform to other BCI companies. Merge launched in January 2026 with $252 million in seed funding to pursue its mission of bridging biological and artificial intelligence.